Table 3.
Cases of severe and non-severe keratitis in MRSE and MSSE groups with good clinical response after 48 hours of empirical treatment.
| Severe (N=29) | Non-severe (N=14) | % total | |||
|---|---|---|---|---|---|
| MRSE (N=13) | MSSE (N=16) | MRSE (N=3) | MSSE (N=11) | ||
| Fluoroquinolones | 3 (100%) | 5 (83%) | 3 (100%) | 7 (100%) | 18 (95%) |
| Ceftazidime + vancomycin | 4 (80%) | 2 (33%) | 0 (0%) | 1 (50%) | 7 (54%) |
| Ceftazidime + tobramycin | 3 (60%) | 3 (75%) | 0 (0%) | 2 (100%) | 8 (73%) |
MRSE: methicillin-resistant Staphylococcus epidermidis, MSSE: methicillin-susceptible Staphylococcus epidermidis.